Skip to content

Vitabalans Pharma OÜ

Registry code (registrikood) 11070110Private limited company (Osaühing)VAT EE100926945Activity (EMTAK 82401): Mujal liigitamata äritegevust abistavate tegevuste vahendamineActive

Tallinn, Harju County · Financial data: annual reports up to 2024; tax data up to 2026 Q3

Revenue (2024)
€1.1M
▲ 10.9% vs 2023
Profit before tax (2024)
€54k
Employees, FTE (2024)
2
State taxes paid, last 4 quarters
€95k

Revenue, profit and employees, 2019–2024

€588k2019€640k2020€737k2021€846k2022€1.0M2023€1.1M2024
YearRevenue (müügitulu)Operating profit (ärikasum)Net profitEquity (omakapital)Employees, FTE
2019€587,728€27,987€27,987€436,4263
2020€639,974€30,475-€29,525€166,9013
2021€737,485€36,785€22,366€103,6853
2022€845,770€40,275€28,375€58,9602
2023€1,029,072€49,004€41,678€55,6382
2024€1,141,472€54,356€44,479€57,8562

Balance sheet summary

YearCashTotal assetsCurrent liabilitiesNon-current liabilitiesEquity
2019€23,670€509,989€73,563—€436,426
2020€34,059€278,153€111,252—€166,901
2021€0€198,435€94,750—€103,685
2022—€163,804€104,844—€58,960
2023—€188,276€132,638—€55,638
2024€32,507€190,753€132,897—€57,856

Calculated ratios

Net profit margin = net profit ÷ revenue. Equity ratio = equity ÷ total assets. Seedata sources & methodology for how each figure is derived.

Quarterly tax and turnover data (EMTA)

QuarterState taxes paidWage taxesTurnoverEmployees
2022 Q1€17,194€15,691€152,1713
2022 Q2€22,820€22,859€221,6943
2022 Q3€17,948€16,994€207,0612
2022 Q4€27,091€27,068€205,4552
2023 Q1€27,714€13,950€210,9212
2023 Q2€15,873€14,790€198,7402
2023 Q3€27,500€27,116€235,1662
2023 Q4€20,013€17,397€260,5662
2024 Q1€22,991€19,294€243,7102
2024 Q2€28,331€18,135€282,1432
2024 Q3€23,351€21,479€293,2452
2024 Q4€31,815€30,395€298,0492
2025 Q1€36,963€24,908€286,3242
2025 Q2€30,341€28,137€301,8802
2025 Q3€26,484€24,488€271,5282
2025 Q4€28,865€27,871€277,6912
2026 Q1€0€23,368€281,4222
2026 Q2€26,109€24,619€289,1562
2026 Q3€39,920€24,815€284,9642

Source: EMTA quarterly published data, as of 10 October 2026. Covers state taxes and wage taxes actually paid and turnover and employee counts as declared by the company, not the annual report figures above.

About this data

In the 2024 financial year (period 1 July 2024–30 June 2025), Vitabalans Pharma OÜ reported revenue of €1,141,472.

The company closed the 2024 financial year with a net profit of €44,479.

Revenue increased by 10.9% from €1,029,072 in 2023 to €1,141,472 in 2024.

Revenue grew at a compound annual rate of 14.2% between 2019 and 2024.

Equity accounted for 30.3% of total assets of €190,753 at the end of the 2024 reporting period.

With 2 full-time-equivalent employees in 2024, revenue per employee was €570,736.

Across the 4 most recent quarters declared to EMTA, up to Q3 2026, Vitabalans Pharma OÜ reported €1,133,233 in turnover.

EMTA recorded 2 employees for the quarter ending Q3 2026, compared with 2 full-time-equivalent employees in the 2024 annual report.

Browse

Source

Source: Estonian e-Business Register open data (Centre of Registers and Information Systems, RIK), licence CC BY-SA 4.0, modified; Estonian Tax and Customs Board (EMTA) quarterly data. Downloaded 2026-11-16. This is not an official register extract — see ariregister.rik.ee.

Company data on this site is available under CC BY-SA 4.0.

To request a correction or the removal of this page, use the contact form. Removal requests are handled within 30 days, no justification required.